Clinical Trial News and Research

RSS

WomanCare Global, Evofem enter strategic alliance

Evofem announced today that it has entered into a strategic alliance with WomanCare Global. Through this alliance, WomanCare Global will provide sales, marketing and global distribution for a selection of Evofem's products, including Softcup and Amphora.

4 Mar 2013

OPKO Health acquires Cytochroma

OPKO Health, Inc. announced that it has completed the acquisition of Cytochroma Inc. Cytochroma's lead products include CTAP101 Capsules, a vitamin D prohormone to treat secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency, and Fermagate Tablets, a new and potent non-absorbed phosphate binder to treat hyperphosphatemia in CKD patients on chronic hemodialysis.

4 Mar 2013

Exercise during pregnancy can reduce rate of cesarean deliveries in healthy pregnant women

Researchers at the Universidad Politécnica de Madrid have found that regular and supervised exercise by experts during pregnancy can reduce the rate of instrumental and cesarean deliveries in healthy pregnant women.

4 Mar 2013

FDA approves Tenaxis Medical’s ArterX Surgical Sealant

Tenaxis Medical, Inc., a medical device company focused on the development of functionally designed surgical sealants has received FDA approval to bring its innovative ArterX Surgical Sealant to the market.

4 Mar 2013

BioClinica, CPI and Medtentia partner for eClinical and Imaging Core Lab solutions

BioClinica, Inc., a global provider of clinical trial management solutions, today announced an agreement for BioClinica Express EDC, data management, and imaging core lab services with Finnish company Medtentia International, in partnership with the contract research organization (CRO) clinicalprojects international (CPI).

From Clario 4 Mar 2013

Idera announces new data from IMO-3100 and IMO-8400 preclinical study on psoriasis

Idera Pharmaceuticals, Inc. today announced the presentation of new data showing that its selective Toll-like receptor antagonists, IMO-3100 and IMO-8400, normalized the gene expression of important cytokines in a preclinical study of skin inflammation that is commonly used as a model of psoriasis.

4 Mar 2013

PsiOxus completes enrollment in MT-102 Phase II trial on cancer cachexia

PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, has completed patient enrollment for its Phase II clinical trial to study MT-102, a small molecule therapeutic for the treatment of cancer cachexia.

4 Mar 2013

Study instructs how to design new, more powerful vaccine formulas for cancer

Cancer vaccines that attempt to stimulate an immune system assault fail because the killer T cells aimed at tumors instead find the vaccination site a more inviting target, scientists at The University of Texas MD Anderson Cancer Center report in Nature Medicine.

4 Mar 2013

Tooth loss due to periodontal disease is more prevalent among postmenopausal women

Postmenopausal women who have smoked are at much higher risk of losing their teeth than women who never smoked, according to a new study published and featured on the cover of the Journal of the American Dental Association by researchers at the University at Buffalo.

2 Mar 2013

Lung congestion increases dialysis patients' risks of premature death or heart attacks

Asymptomatic lung congestion increases dialysis patients' risks of dying prematurely or experiencing heart attacks or other cardiac events, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

1 Mar 2013

Pivotal study of olesoxime in Spinal Muscular Atrophy receives positive interim review

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for under-served medical needs in neurology and cardiology, announced the completion of the interim analysis of the pivotal efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy (SMA).

1 Mar 2013

Urea cycle disorder patient successfully treated by Promethera(R) HepaStem in Phase I/II trial in France

Promethera Biosciences, a Belgian biotechnology company developing Promethera(R) HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announced that it has successfully treated a patient with liver progenitor cells enrolled in its Phase I/II trial.

1 Mar 2013

Oraya Therapy safe and effective for patients with wet AMD

Oraya Therapeutics, Inc. today announced that one of the patients who successfully was treated for wet age-related macular degeneration (AMD) with Oraya Therapy during the INTREPID clinical trial has released data showing he has experienced significant, sustained vision improvement more than two years after treatment in his right eye, without any subsequent anti-vascular endothelial growth factor (anti-VEGF) injections or other treatment.

1 Mar 2013

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced the U.S. Food and Drug Administration (FDA) has approved ABILIFY MAINTENA (aripiprazole) for extended- release injectable suspension, an intramuscular (IM) depot formulation indicated for the treatment of schizophrenia.

1 Mar 2013

TikoMed, BRI partner to investigate IBsolvMIR in phase II trial for chronic pancreatitis

Baylor Research Institute (BRI), the research arm of Baylor Health Care System, and TikoMed AB announced today that an agreement has been established to investigate TikoMed´s product IBsolvMIR® in a phase II clinical trial.

28 Feb 2013

Mutant HSP70i protein may offer potent treatment opportunities for vitiligo

Loyola University Chicago Stritch School of Medicine researchers have developed a genetically modified protein that dramatically reverses the skin disorder vitiligo in mice, and has similar effects on immune responses in human skin tissue samples.

28 Feb 2013

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2012, and provided an update on the Company's merger with Immune Pharmaceuticals, Ltd. (Immune).

28 Feb 2013

Inviragen to initiate second stage of DENVax Phase 2 study in dengue

Inviragen, Inc. today announced the initiation of the second stage of an ongoing Phase 2, randomized, double-blind, placebo-controlled study of DENVax, the Company's investigational dengue vaccine.

27 Feb 2013

CellAegis Devices to use autoRIC Device for Chronic Remote Ischemic Conditioning

CellAegis Devices, Inc., announced today that it has received an Investigational Testing Approval from Health Canada that allows the initiation of clinical testing in Canada of the Company's autoRIC Device for Chronic Remote Ischemic Conditioning (CRIC).

27 Feb 2013

HeartWare International fourth quarter revenue increases 42% to $32.7 million

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $32.7 million for the fourth quarter ended December 31, 2012, a 42% increase compared to $23.1 million in revenue for the same period of 2011.

27 Feb 2013

Clinical Trial News and Research

WomanCare Global, Evofem enter strategic alliance

OPKO Health acquires Cytochroma

Exercise during pregnancy can reduce rate of cesarean deliveries in healthy pregnant women

FDA approves Tenaxis Medical’s ArterX Surgical Sealant

BioClinica, CPI and Medtentia partner for eClinical and Imaging Core Lab solutions

Idera announces new data from IMO-3100 and IMO-8400 preclinical study on psoriasis

PsiOxus completes enrollment in MT-102 Phase II trial on cancer cachexia

Study instructs how to design new, more powerful vaccine formulas for cancer

Tooth loss due to periodontal disease is more prevalent among postmenopausal women

Lung congestion increases dialysis patients' risks of premature death or heart attacks

Pivotal study of olesoxime in Spinal Muscular Atrophy receives positive interim review

Urea cycle disorder patient successfully treated by Promethera(R) HepaStem in Phase I/II trial in France

Oraya Therapy safe and effective for patients with wet AMD

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

TikoMed, BRI partner to investigate IBsolvMIR in phase II trial for chronic pancreatitis

Mutant HSP70i protein may offer potent treatment opportunities for vitiligo

EpiCept fourth quarter revenue decreases to $0.1 million

Inviragen to initiate second stage of DENVax Phase 2 study in dengue

CellAegis Devices to use autoRIC Device for Chronic Remote Ischemic Conditioning

HeartWare International fourth quarter revenue increases 42% to $32.7 million

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer